Bioblast Pharma

Hope should not be rare

Leadership team

The Leadership Team for Bioblast Pharma

A shared commitment to the future for patients and their families

Determined to be leaders in innovation and bring therapeutic breakthroughs to patients with rare and ultra-rare genetic diseases is a team of passionate professionals. With a collective experience that spans global markets, varying disciplines, and numerous medical industries, our Bioblast Pharma leadership team will not waver until our company’s goals are realized.

Learn about the members of the Bioblast leadership team
  • Fredric Price

    Executive Chairman of the Board of Directors

    Fredric Price has been Executive Chairman of our Board of Directors since April 2014, having served as Chairman of the Board of Directors from April 2012 until April 2014.

    Learn more
  • Warren Wasiewski

    Warren Wasiewski, MD

    Chief Medical Officer and Vice President of Research and Development

    Warren Wasiewski, MD, is a board-certified pediatric neurologist with 22 years of clinical experience in pediatric neurology and 15 years of experience in the pharmaceutical industry.

    Learn more
  • Zohar Argov

    Professor Zohar Argov, MD

    Special Medical Advisor to CEO

    Professor Zohar Argov, MD, is world renowned for his studies and discoveries in myology and neurological diseases.

    Learn more
  • Chaime Orlev

    Chaime Orlev

    CFO and VP Finance & Administration

    Chaime Orlev joined Bioblast in September 2016. Prior to Bioblast, between 2011 to 2016, Mr. Orlev was Vice President, Finance and Administration in Chiasma (NASDAQ: CHMA), a biopharma company focused on improving the lives of patients with rare diseases, where he was instrumental in Chiasma’s multiple fund raising rounds and in taking the company through its successful IPO.

    Learn more
  • Dana Gelbaum

    Chief Commercial Officer

    Dana Gelbaum joined Bioblast in November 2016, bringing expertise in developing commercial strategy of clinical stage investigational drugs for rare diseases.

    Learn more